Compare DexCom, Inc. (DXCM) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs InMode Ltd — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while InMode Ltd trades at $14.22 (market cap $809.93M). The key difference: DexCom, Inc. is far larger — about 39.3× InMode Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and InMode Ltd for 28 Days on average.
| DXCM | INMD | |
|---|---|---|
Market Cap | $31.86B | $809.93M |
Volume | 3,607,070 | 365,490 |
Sector | Health | Health |
52-Week High | $92.34 | $16.62 |
52-Week Low | $54.84 | $12.76 |
Typical Hold Time | 62 Days | 28 Days |
Enterprise Value | $31.32B | $313.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
INMD trades at $14.20, up 1.36% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with 76.52% gross margins and 20.69% net income margin, though Q1 2026 earnings missed expectations. Recent news includes product innovation with Morpheus8 Cool launch and an unsolicited acquisition offer from Steel Partners at $16.75 per share. Analyst consensus is divided with 45% buy ratings amid ongoing shareholder activism concerns.
The stock presents value opportunity with attractive valuation multiples (P/E 11.63, EV/EBITDA 4.48) but faces near-term execution risks. Key catalysts include Q3 earnings delivery and resolution of acquisition talks, while risks involve management credibility and competitive pressures in aesthetic medicine markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
